URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Carman Alenson Biography and Net Worth

Insider of Agios Pharmaceuticals

Currently, Carman Alenson is Vice President-Accounting, Treasury & Tax at Agios Pharmaceuticals, Inc.

She received an MBA and an undergraduate degree from Boston University.

What is Carman Alenson's net worth?: The estimated net worth of Carman Alenson is at least $71,044.46 as of June 21st, 2021. Ms. Alenson owns 1,777 shares of Agios Pharmaceuticals stock worth more than $71,044 as of December 18th. This net worth estimate does not reflect any other investments that Ms. Alenson may own. Learn More about Carman Alenson's net worth.
How do I contact Carman Alenson?: The corporate mailing address for Ms. Alenson and other Agios Pharmaceuticals executives is 88 SIDNEY STREET, CAMBRIDGE MA, 02139. Agios Pharmaceuticals can also be reached via phone at (617) 649-8600 and via email at [email protected]. Learn More on Carman Alenson's contact information.
Has Carman Alenson been buying or selling shares of Agios Pharmaceuticals?: Carman Alenson has not been actively trading shares of Agios Pharmaceuticals during the last ninety days. Most recently, Carman Alenson sold 1,777 shares of the business's stock in a transaction on Monday, June 21st. The shares were sold at an average price of $61.61, for a transaction totalling $109,480.97. Following the completion of the sale, the insider now directly owns 1,777 shares of the company's stock, valued at $109,480.97. Learn More on Carman Alenson's trading history.
Who are Agios Pharmaceuticals' active insiders?: Agios Pharmaceuticals' insider roster includes Carman Alenson (Insider), Jonathan Biller (CFO & Head of Corp. Affairs ), Christopher Bowden (Insider), James Burns (https://www.linkedin.com/in/jackie-fouse-a90b811aa), Jacqualyn Fouse (CEO & Director ), Jacqualyn Fouse (Director), Sarah Gheuens (Chief Medical Officer, Head of R&D), Brian Goff (CEO), Cecilia Jones (CFO), and Darrin Miles (Insider). Learn More on Agios Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Agios Pharmaceuticals?: In the last year, insiders at the biopharmaceutical company sold shares 17 times. They sold a total of 76,341 shares worth more than $2,120,143.90. The most recent insider tranaction occured on December, 11th when Director David Scadden sold 200 shares worth more than $9,256.00. Insiders at Agios Pharmaceuticals own 4.9% of the company. Learn More about insider trades at Agios Pharmaceuticals.
Information on this page was last updated on 12/11/2024.

Carman Alenson Insider Trading History at Agios Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/21/2021	Sell	1,777	$61.61	$109,480.97	1,777
4/15/2021	Sell	991	$54.00	$53,514.00
9/2/2020	Sell	250	$39.93	$9,982.50	184
12/26/2019	Sell	2,950	$50.09	$147,765.50
7/9/2018	Sell	272	$84.94	$23,103.68	272
1/12/2018	Sell	2,150	$75.00	$161,250.00	2,150

Carman Alenson Buying and Selling Activity at Agios Pharmaceuticals

Agios Pharmaceuticals Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $39.98

$39.75

$42.36

50 Day Range

MA: $50.09

$38.17

$61.64

2 Week Range

Now: $39.98

$20.96

$62.58

Volume

472,855 shs

Average Volume

719,692 shs

Market Capitalization

$2.28 billion

P/E Ratio

3.52

Dividend Yield

N/A

Beta

0.8

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now